Aspirin to be tested as a potential COVID-19 treatment as pa
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Scientists reported that Aspirin would be part of the world’s largest clinical trial of treatments for patients infected with SARS-CoV-2, called the Randomised Evaluation of COVID-19 therapy (RECOVERY) trial.

The RECOVERY trial is ongoing in 176 hospitals across the UK – and has enrolled more than 16,000 patients.

It is still unclear if any of the drugs under study could help people recover faster than the usual standard of hospital care. The suggested treatments include Tocilizumab, Azithromycin, low-dose Dexamethasone, convalescent plasma, REGN-COV2 (monoclonal antibodies), and Aspirin.

Adding Aspirin:

Aspirin, also known as acetylsalicylic acid, is a 120-year-old drug used to reduce pain, fever, or inflammation. It is widely used in conditions such as pericarditis, Kawasaki disease, and rheumatic fever, among others.

People infected with SARS-CoV-2 seem to have hyperactive platelets and these patients are at a higher risk of potentially fatal blood clots, which can cause strokes.

Health experts believe that Aspirin, which is also used as an antiplatelet and blood thinner, can help reduce the odds of clotting complications amid a COVID-19 infection.

At least 2,000 patients are expected to be randomly administered 15 mg of Aspirin daily, along with their usual treatments. The investigators will compare the data from these patients to another 2,000 patients who received just the standard of care for COVID-19.

Further, patients with sensitivity or allergy to Aspirin, with recent major bleeding, or have recently taken Aspirin, or other antiplatelet agents will be excluded from the study.

The RECOVERY trial’s primary outcome will evaluate mortality after 28 days. The other outcomes include the impact on hospital stay and the need for mechanical ventilation. The researchers noted that it might take several months before there is adequate evidence to conclude whether Aspirin could benefit COVID-19 patients.

s●●●●m s●●●●a and 1 others like this3 shares